Ann: Botanix $70 Million Institutional Capital Raising, page-225

The re-rate will come as soon as sales start perking up. Yet again, caution will be exercised for our sales team, people who could sell a comb to baldman.
The analytical reports showing sales trajectories are in deed remarkable but the market won't buy that yet. They need to deliver and they need to then welcome us all into the pleasuredome. Relax, when you wanna go do it. Marsman is now relaxed, not fixated with one eye ball focused on the words of a poster and the right eye ball focussed on the top right here's ASX delayed share price.Howie and all have shot us in the direction, they have made it their intention. We will all live our dreams, we can scheme our schemes and we will grow no sweat. In the meantime, i am sure the team is on the lookout for distressed assets and companies that could deal with a bit of tweaking. What about this one who could do with a lot of tweaking.
An experimental medicine that Jazz Pharmaceuticals picked up in 2019 has failed a mid-stage study testing it against essential tremor. Researchers evaluated three doses of the medicine in 420 participants. They found the highest dose didn’t meet the study’s main or secondary goals, though there were “numeric improvements” that hinted at some benefit. According to Jazz’s research and development head, the company will wait for results from a separate trial focused on Parkinson’s disease tremor before making a decision on next steps for the program. Those data are expected to come early next year. Should Botanix buy this distressed company and call it Jizz Pharmaceuticals instead ? Frankie would approve on his way to Hollywood.